ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CRON vs RGC // EV/EBITDA & P/E VALUATION

Cronos Group Inc. Common Share (NASDAQ) VS. Regencell Bioscience Holdings Limited (NASDAQ) • 15-METRIC TALLY: CRON 3 — RGC 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRON VS. RGC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CRON RGC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 42.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -4.50% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield 0.01% -0.10% +0.11 CRON /fcf-yield <GO>
Operating Margin -11.90% — — TIE /operating-margins <GO>
Net Profit Margin -2.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 24.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 15.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 2/9 +4.00 CRON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.4 42.8 +7.62 CRON /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.24B $3.40B -$2.16B RGC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CRON REV RGC REV CRON GROSS % RGC GROSS % CRON FCF RGC FCF
FY 2025 $146.6M $0 42.8% — $149.0K -$3.3M
FY 2024 $117.6M $0 21.4% — $6.4M -$4.0M
FY 2023 $87.2M $0 — — -$42.8M -$5.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRON // BETA —
RGC // BETA —